Evidence map›Paper›PMID 42223836›Full record

ArticleClinical journal of gastroenterology2026

A case of miliary tuberculosis after prophylactic therapy for latent tuberculosis.

Hirotaka Kashima, Taro Ueo, Akihisa Fukuda, Hiroshi Seno

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Clinical journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hirotaka KashimaDepartment of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawahara-Cho Sakyo-Ku, Kyoto, 606-8507, Japan. hirotakak@kuhp.kyoto-u.ac.jp.
Taro UeoDepartment of Gastroenterology, Tenri Hospital, 200 Mishima-Cho, Tenri, Nara, 632-8552, Japan.
Akihisa FukudaDepartment of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawahara-Cho Sakyo-Ku, Kyoto, 606-8507, Japan.
Hiroshi SenoDepartment of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawahara-Cho Sakyo-Ku, Kyoto, 606-8507, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 74-year-old man was referred to our hospital with persistent fever and fatigue. He had been receiving Golimumab for rheumatoid arthritis for 15 months. At the time of GLM initiation, latent tuberculosis (TB) was suspected, and Isoniazid was prophylactically administered for 8 months. Fifteen months after Golimumab initiation, he developed the symptoms. Reactivation of latent TB was suspected, however, chest and abdominal CT revealed no abnormal findings, and acid-fast bacillus smear and PCR tests from sputum, urine, blood, and gastric juice samples were negative for TB. Given that blood tests showed elevated hepatobiliary enzymes, miliary TB was suspected, and liver biopsy was performed, revealing caseous necrosis. Therefore, he was diagnosed with reactivation of latent TB caused by INH-resistant Mycobacterium tuberculosis. Following the treatment of rifampicin, ethambutol, levofloxacin, and streptomycin, the fever quickly resolved, and hepatobiliary enzyme levels were normalized. Culture of the liver biopsy tissue for acid-fast bacilli yielded INH-sensitive Mycobacterium tuberculosis. Although very rare, our case underscores that careful observation for reactivation of latent TB is important for patients receiving TNFα inhibitors even after appropriate prophylactic treatment for latent TB. Liver biopsy should be considered, when elevated liver enzymes are observed in suspected cases of miliary TB.

Indexed as

Antirheumatic AgentsAntitubercular AgentsLatent TuberculosisTuberculosis, MiliaryAgedAntibodies, MonoclonalArthritis, RheumatoidBacilloscopyHumansIsoniazidMaleMycobacterium tuberculosisTumor Necrosis Factor-alphaAntibodies, MonoclonalAntirheumatic AgentsAntitubercular AgentsgolimumabIsoniazidTumor Necrosis Factor-alphaLatent tuberculosisMiliary tuberculosisTNFα inhibitor

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.